Adage Capital Partners GP L.L.C. Invests $3.62 Million in Atyr PHARMA INC (NASDAQ:ATYR)

Adage Capital Partners GP L.L.C. acquired a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,000,000 shares of the company's stock, valued at approximately $3,620,000. Adage Capital Partners GP L.L.C. owned about 1.19% of Atyr PHARMA as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ATYR. Alterna Wealth Management Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter worth about $36,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter valued at $37,000. Raymond James Financial Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter valued at $39,000. XTX Topco Ltd purchased a new stake in Atyr PHARMA during the 4th quarter worth $40,000. Finally, JPMorgan Chase & Co. increased its holdings in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock valued at $55,000 after purchasing an additional 10,754 shares in the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ATYR has been the subject of several analyst reports. Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an "overweight" rating on the stock. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Stock Performance

Shares of Atyr PHARMA stock traded down $0.09 during trading hours on Monday, reaching $3.52. The company's stock had a trading volume of 283,730 shares, compared to its average volume of 902,539. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA INC has a one year low of $1.42 and a one year high of $4.66. The company's 50 day simple moving average is $3.29 and its 200 day simple moving average is $3.40. The stock has a market cap of $312.34 million, a P/E ratio of -3.75 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. As a group, analysts expect that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.